ARISTOTLE LABORATORIES
Refounding Medicine
VISION
Eroom’s Law teaches us medicine is broken. We are not getting better at producing therapies. We are getting worse. Aristotle Laboratories believes a rebuild is needed. Tinkering with parts won’t turn a clunker into a rocket ship.
​
We describe the details of our approach in a forthcoming white paper. In brief, we are deleting preclinical research and much regulatory encumberment by using systems theory and artificial intelligence to combine interventions already approved by the FDA into novel therapies; reducing cycle time and costs by prioritizing severe, rapidly progressing diseases apt for reliably toxicity-reducing routes of administration; and pioneering higher-potential trial designs by using a proprietary apparatus, artificial intelligence, and regulatory arbitrage to accomplish platformed, massively parallel, continuously iterating n=1 experiments.
​
​
TEAM
Phil Murray and Andrew Mitchell met as colleagues at a Boston-based venture studio. Observing firsthand the slow pace of even the most innovative biotech companies, they grew disillusioned. Each left to pursue other projects. However, over the years, their conversations kept returning to the question of how they might do better. Aristotle Laboratories is the product of those conversations.
Phil serves as CEO. He has founded multiple neurotechnology startups and is a co-inventor of the combination therapy marketed under the trade name Cobenfy. He holds a BS in mechanical engineering from MIT.
​
Andrew serves as CTO. He is a multi-industry entrepreneur with experience in non-dilutive fundraising. He holds a PhD in biochemistry from Harvard University.
​
